The Ottawa Hospital Research Institute

Purpose

The Recipient is proposing to take advantage of previous government investments in GMP manufacturing facilities in Alberta and Ontario to create a cohesive, collaborative team approach for the production of life-saving virus-based therapeutics. The Recipient's internationally recognized track record of producing GMP grade virus products is unrivalled in Canada. The Recipient has in place, a team of highly skilled and qualified personnel who have made virus-based products for the last decade that have and continue to be used in human clinical trials around the world. The Recipient's plan is to sue this team and upgraded facilities to rapidly create a pipeline that generates novel vectors for the treatment of rare diseases such as Lipoprotein Lipase Deficiency a disease which particularly impacts French Canadian Families. Working closely with Scientist from the National Research Council, the Recipient will optimize manufacturing processes to efficiently and economically create novel medicines that are affordable to the Canadian Healthcare System and accessible to all Canadians in need.